Primary Dural Diffuse Large B-cell Lymphoma: A Comprehensive Review of Survival and Treatment Outcomes

Publication date: Available online 28 September 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Zachary L. Quinn, Karam Zakharia, Janet L. Schmid, John J. Schmieg, Hana Safah, Nakhle S. SabaAbstractPrimary dural diffuse large B-cell lymphoma (PD-DLBCL) is a rare and aggressive B-cell non-Hodgkin lymphoma (NHL) that can present in intracranial or intraspinal locations. While the optimal management is unknown, PD-DLBCL therapy is often mirrored after primary central nervous system lymphoma (PCNSL) therapy and aggressive treatment with a high dose Methotrexate (MTX)-based regimen is frequently used. Our comprehensive, retrospective study of 24 reported cases of PD-DLBCL provide the most complete analysis of this rare disease including data on biology, treatment outcomes and survival. Our findings demonstrate good outcomes following induction treatment with R-CHOP, suggesting that these cases can be treated as DLBCL rather than PCNSL, obviating the need for more aggressive and toxic approaches. The durable responses following R-CHOP also confirm that PD-DLBCL is not protected by the blood brain barrier. Data in this paper were presented in part at the 2017 American Society of Hematology Annual Meeting, abstract # 4166.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research